Uremic Pruritus
Conditions
Keywords
Hemodialysis, Pruritus, Uremic Pruritus, Dialysis, CR845, Difelikefalin, Chronic Itch, CKD, CKD-associated pruritus, CKD-aP, ESRD (end stage renal disease), Itch, Itching, KALM, Chronic Kidney Disease, Kidney failure, chronic, Kidney dysfunction, Generalized pruritus, Expanded access, Compassionate use
Brief summary
This is an intermediate-size patient population expanded access protocol for the use of intravenous (IV) difelikefalin for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients undergoing hemodialysis.
Detailed description
Visits during the expanded access program will consist of a Baseline Visit to confirm eligibility and an End of Treatment visit. Patients will receive IV difelikefalin at a dose of 0.5 mcg/kg after each dialysis session, generally 3 times per week. The End of Treatment visit will be defined as the first dialysis visit following the last dose of IV difelikefalin under the intermediate-size patient population expanded access protocol.
Interventions
DRUGDifelikefalin
IV Difelikefalin 0.5 mcg/kg administered after each dialysis session (3 times/week)
Sponsors
Cara Therapeutics, Inc.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
Key Inclusion Criteria: * Adults ≥ 18 years old; * Has end-stage renal disease (ESRD) and is currently receiving in-center hemodialysis; * Has moderate-to-severe pruritus attributed to ESRD which is significantly impacting the patient's quality of life; * Has no comparable or satisfactory alternative therapy for the treatment of moderate-to-severe pruritus, as determined by the sponsor-investigator. Key
Exclusion criteria
* Has severe hepatic impairment (Child-Pugh class C), as the influence of severe hepatic impairment on the pharmacokinetics of difelikefalin has not been evaluated; * Is pregnant or nursing; * Has been exposed to any other investigational medication in the past 60 days; * Present any other reason which may lead to an unfavorable risk-benefit ratio for treatment with difelikefalin, as determined by the sponsor-investigator; * Has a known or suspected allergy to difelikefalin or any component of the investigational product.
Outcome results
None listed